Results 181 to 190 of about 38,631 (238)
Efficacy and safety of phosphodiesterase type 5 inhibitors for the treatment of distal ureteral calculi of 5 to 10 mm in size: A systematic review and network meta-analysis. [PDF]
Kaohsiung J Med Sci, 2019 Li JK +9 more
europepmc +1 more source
Comparison of phosphodiesterase type 5 (PDE5) inhibitors
International Journal of Clinical Practice, 2006 openaire +1 more source
In Salmonella Typhimurium, YiiD Modulates cAMP Levels in Lag Phase During Growth on Succinate
Molecular Microbiology, Volume 126, Issue 1, Page 15-23, July 2026.The YiiD enzyme, found by others to perform a redundant role in fatty acid biosynthesis, is found to be unexpectedly required for the early increase in cAMP in lag phase during growth on succinate. This intriguing finding suggests a mechanistic link may exist between fatty acid biosynthesis and catabolite repression. ABSTRACT In Salmonella Typhimurium (
John A. Ciemniecki +2 more
wiley +1 more source
Phosphodiesterase type 5 inhibitors: Irrational use in Saudi Arabia. [PDF]
Arab J Urol, 2016 Alshahrani S +6 more
europepmc +1 more source
Molecular Microbiology, Volume 126, Issue 1, Page 98-110, July 2026.Single amino acid substitutions in the global regulator CodY can alter nutrient sensing and virulence regulation in Clostridioides difficile. We show that the CodY(Y146N) and CodY(V58A) variants display altered ligand binding and reduced promoter binding, leading to derepression of toxin regulatory pathways and increased virulence in vivo.
Md Kamrul Hasan +2 more
wiley +1 more source
The Journal of Physiology, Volume 604, Issue 13, Page 5236-5259, 1 July 2026.Abstract figure legend AC: adenylyl cyclase, APT: adenosine triphosphate, AMP: adenosine monophosphate, cAMP: cyclic adenosine monophosphate, PDE: phosphodiesterase, PKA: protein kinase A, PPT: protein phosphatase, P: phosphorylation, RyR: ryanodine receptor, SERCA: sarcoplasmic/endoplasmic reticulum Ca2+‐adenosine triphosphatase, SR: sarcoplasmic ...
Moritz Linder +4 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Phosphodiesterase Type 5 Inhibitors: The Day After
European Urology, 2007Review the literature on phosphodiesterase type 5 inhibitors (PDE5-Is), addressing critical issues in their current and future use, assessing unanswered questions, and identifying research needs.A MEDLINE search was conducted on PDE5-Is, with emphasis on clinical trials and experience, for interpretation and analysis of their present and future role ...
Konstantinos, Hatzimouratidis +1 more
openaire +2 more sources
Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design, 2009Erectile dysfunction (ED) has been revolutionized during the last two decades, as several treatment options are available today. Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are currently the first choice treatment option for ED by most physicians and patients due to their high efficacy rates and favourable safety ...
K, Hatzimouratidis, D G, Hatzichristou
openaire +2 more sources
Phosphodiesterase type 5 inhibitors for erectile dysfunction
BJU International, 2005This is our first presentation of Great Drug Classes, and we start with a description of phosphodiesterase type 5 inhibitors and their use in erectile dysfunction. This is an in‐depth review of this class of drugs, offering the reader a description of how they work, in which conditions they may be particularly beneficial, and a ...
Culley C, Carson, Tom F, Lue
openaire +2 more sources
Phosphodiesterase type 5 inhibitors and kidney disease
International Urology and Nephrology, 2015Chronic kidney disease (CKD) represents a worldwide health problem. Traditionally, the nephroprotective treatment for CKD aims to slow progression to end-stage renal disease and includes dietary protein restriction, correction of metabolic acidosis, and renin-angiotensin system blockers.
Baris, Afsar +6 more
openaire +2 more sources